Fulgent Genetics Stock Current Ratio
| FLGT Stock | USD 20.64 0.08 0.39% |
Fulgent Genetics fundamentals help investors to digest information that contributes to Fulgent Genetics' financial success or failures. It also enables traders to predict the movement of Fulgent Stock. The fundamental analysis module provides a way to measure Fulgent Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fulgent Genetics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.96 | 7.46 |
Fulgent | Current Ratio |
Fulgent Genetics Company Current Ratio Analysis
Fulgent Genetics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Fulgent Genetics Current Ratio | 5.29 X |
Most of Fulgent Genetics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulgent Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fulgent Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Fulgent Genetics is extremely important. It helps to project a fair market value of Fulgent Stock properly, considering its historical fundamentals such as Current Ratio. Since Fulgent Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulgent Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulgent Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Fulgent Current Ratio Historical Pattern
Today, most investors in Fulgent Genetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fulgent Genetics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Fulgent Genetics current ratio as a starting point in their analysis.
Fulgent Genetics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Fulgent Discontinued Operations
Discontinued Operations |
|
In accordance with the recently published financial statements, Fulgent Genetics has a Current Ratio of 5.29 times. This is 81.79% higher than that of the Health Care Providers & Services sector and 18.61% higher than that of the Health Care industry. The current ratio for all United States stocks is 144.91% lower than that of the firm.
Fulgent Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulgent Genetics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics of similar companies.Fulgent Genetics is currently under evaluation in current ratio category among related companies.
Fulgent Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0347 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 199 M | ||||
| Shares Outstanding | 29.9 M | ||||
| Shares Owned By Insiders | 32.58 % | ||||
| Shares Owned By Institutions | 49.08 % | ||||
| Number Of Shares Shorted | 603.98 K | ||||
| Price To Earning | 3.95 X | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 289.21 M | ||||
| Gross Profit | 366.9 M | ||||
| EBITDA | (43.54 M) | ||||
| Net Income | (167.82 M) | ||||
| Cash And Equivalents | 515.4 M | ||||
| Cash Per Share | 17.03 X | ||||
| Total Debt | 14.91 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 38.31 X | ||||
| Cash Flow From Operations | 27 M | ||||
| Short Ratio | 2.23 X | ||||
| Earnings Per Share | (5.63) X | ||||
| Price To Earnings To Growth | 1.32 X | ||||
| Target Price | 26.67 | ||||
| Number Of Employees | 1.18 K | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 614.76 M | ||||
| Total Asset | 1.27 B | ||||
| Retained Earnings | 633.17 M | ||||
| Working Capital | 434.83 M | ||||
| Current Asset | 2.93 M | ||||
| Current Liabilities | 686 K | ||||
| Net Asset | 1.27 B |
About Fulgent Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulgent Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fulgent Genetics Piotroski F Score and Fulgent Genetics Altman Z Score analysis. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.